| Bioactivity | Cedazuridine (E7727) (Compound 7a) hydrochloride is an orally active cytidine deaminase (CDA) inhibitor with an IC50 value of 0.4 μM. Cedazuridine hydrochloride can be used for cancer research[1]. |
| Target | IC50: 0.4 μM (CDA) |
| Invitro | Cedazuridine (Compound 7a) exhibits superior acid stability[1].Cedazuridine (0-10 μM; 72 h) does not enhance effects of AZA (5-Azacytidine, HY-10586) in growth inhibition of AML cell lines[2]. |
| In Vivo | Cedazuridine (3 mg/kg; p.o.; daily for 7 days) in combination with 2.5 mg/kg AZA shows tumor regression in mice MOLM-13 CDX and PDX models[2]. Animal Model: |
| Name | Cedazuridine hydrochloride |
| Formula | C9H15ClF2N2O5 |
| Molar Mass | 304.68 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Ferraris D, et al. Design, synthesis, and pharmacological evaluation of fluorinated tetrahydrouridine derivatives as inhibitors of cytidine deaminase. J Med Chem. 2014 Mar 27; 57(6):2582-8. [2]. Ramsey H E, et al. Oral azacitidine and cedazuridine approximate parenteral azacitidine efficacy in murine model. Targeted Oncology, 2020, 15(2): 231-240. |
Cedazuridine hydrochloride
CAS: F: C9H15ClF2N2O5 W: 304.68
Cedazuridine (E7727) (Compound 7a) hydrochloride is an orally active cytidine deaminase (CDA) inhibitor with an IC50 val
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.